Canada's Cannabis Industry Warns of Losing Global Trade Edge

The Canadian cannabis sector is pressing the federal government to leverage surging medical exports as a strategic tool in diversifying trade away from the United States. Industry leaders argue that without immediate diplomatic and logistical support, Canada risks losing its position as a premier global supplier to more aggressive international competitors.

According to The Globe and Mail, foreign sales of Canadian cannabis are on track to exceed one billion dollars this year, with projections indicating a doubling of that figure by 2027. Despite these growing numbers, the industry contends that Ottawa is largely absent from trade missions and fails to address bureaucratic barriers that hinder international shipments.

Industry leaders cite persistent bureaucratic hurdles

Miguel Martin, chief executive officer of Aurora Cannabis Inc., warned that the sector cannot remain static while the rest of the world expands its capacity. He noted that major markets in Europe, including Spain, France, and Italy, are establishing medical cannabis regimes and seeking reliable suppliers, yet Canada is playing a minimal role in these discussions.

Rick Savone, Aurora’s senior vice-president of government relations and former ambassador to Brazil, attributed the government’s reluctance to the enduring stigma surrounding the industry. He compared the situation to other major Canadian exporters, noting that despite employing more people and generating significant tax revenue, cannabis executives struggle to secure high-level government attention.

Ukraine illustrates the potential for new markets

The expansion of the medical cannabis market offers a concrete example of untapped opportunity. Ukraine, which recently legalized medical cannabis, has expressed interest in learning from Canada’s experience in treating veterans with post-traumatic stress disorder. Estimates suggest the Ukrainian market could serve between six and ten million patients by the end of the decade.

Olga Stefanishyna, a Ukrainian politician who participated in a 2024 delegation to an Aurora facility in Germany, emphasized the desire to strengthen collaboration with Canadian partners. Since Ukraine does not have domestic production capacity, it relies on international suppliers, making Canadian companies well-positioned to fill this demand if supported by the state.

Competitors aim to capture emerging global demand

Governments in Thailand, Colombia, and South Africa are actively supporting their own domestic industries to expand exports, creating a competitive threat to Canadian dominance. James Yamanaka, CEO of Organigram Global, assessed that Canada has a narrow window of two to three years before rivals close the gap in quality and market access.

The industry is not requesting financial subsidies but rather recognition of the export opportunity and assistance with logistics. As new countries establish regulatory frameworks for medical cannabis, the next few years will determine whether Canada can maintain its competitive advantage or cedes ground to emerging producers.